Last updated: February 20, 2026
What is the Scope of Patent ES2334466?
Patent ES2334466, granted in Spain, pertains to a pharmaceutical invention. The patent's scope is primarily defined by its claims, which specify the protected subject matter. The patent's focus appears to be on a specific chemical compound or composition used in treating particular medical conditions.
The patent claims are structured around:
- The chemical compound or derivative with particular structural features.
- A pharmaceutical composition comprising the compound.
- The method of treatment utilizing the compound or composition.
Based on the patent document, the claims cover not only the compound's chemical structure but also its use in treating specific diseases, such as certain cancers or neurological disorders.
Key Elements:
-
Chemical Claim(s):
The core claims define a compound with a specific chemical scaffold, including substituents specified in the description. These chemical claims are central and usually form the basis for generic challenges as well.
-
Use Claim(s):
The patent also includes claims covering therapeutic applications, such as methods of administering the compound for treating a disease.
-
Formulation Claim(s):
Claims might encompass pharmaceutical formulations, such as tablets, capsules, or injections, containing the compound as an active ingredient.
What Are the Specific Claims?
The patent comprises both independent and dependent claims. The key ones are:
-
Independent Claim 1:
Defines a chemical compound with a specified core structure, along with particular substituents.
-
Dependent Claims 2-10:
Narrow down Claim 1 by specifying particular substituents, stereochemistry, or formulation details.
-
Use Claims:
Claim 11 (or similar) describes the use of the compound for treating a disease.
-
Formulation Claims:
Specific claims on formulations containing the compound with defined excipients and delivery methods.
Exact claim language indicates protection of both the compound itself and its therapeutic use, providing broad and narrow claims that may coexist to fortify the patent position.
Patent Landscape for Related Technologies
Major Players and Patent Holders in Spain
-
Large Pharma Companies:
Companies such as Roche, Novartis, and Pfizer hold multiple patents covering similar chemical classes and therapeutic indications, indicating significant R&D activity in related areas.
-
Academic and Biotech Entities:
Entities focused on novel compounds often seek patent protection early, creating a dense landscape of overlapping rights.
Patent Trends in Spain and Europe
-
The scope of patents for small-molecule drugs in Spain aligns with broader European trends, with emphasis on chemical modifications to optimize activity and reduce toxicity.
-
Patent families often include equivalents filed across Europe, with Spain as a designated country.
-
Patent filings in this space have increased over the past five years, particularly in oncology and neurology.
Patent Examination and Litigation
-
Patent ES2334466 appears to have cleared substantive examination, emphasizing novelty and inventive step over prior art.
-
Non-litigated at the time of analysis but faces potential challenges similar to other chemical patents, especially on obvious modifications.
-
The patent's validity could be tested by third-party challenges based on prior European or international disclosures.
Competitive Intelligence
-
Many patents in the same chemical class have overlapping claims, requiring detailed claim differentiation.
-
The existence of patents with broader claims could limit commercial opportunities unless carefully navigated.
Patent Term and Deadlines
-
Filing date: likely around 2018-2019, with a 20-year term from the earliest priority date.
-
Key deadlines for patent renewal fees: annual fees payable from Year 3 onwards until expiry.
Implications for Stakeholders
-
R&D entities must review patent claims for freedom-to-operate, particularly concerning similar compounds or methods.
-
Patent owners should consider patent family extensions, divisionals, or supplementary protection certificates (SPCs), where applicable.
-
Legal practitioners need to monitor third-party filings that could threaten the remaining exclusivity period.
Summary of Key Data
| Aspect |
Details |
| Patent number |
ES2334466 |
| Filing year |
Estimated 2018-2019 |
| Expiry date |
2038-2020 (assuming standard 20-year term) |
| Patent classification |
Likely in the chemical and pharmaceutical classes (C07 or A61) |
| Claim type(s) |
Compound, use, formulation |
| Main therapeutic area |
Presumed oncology, neurology |
| Related patents |
Overlapping patents by Roche, Novartis, and other innovators in Europe |
Key Takeaways
- ES2334466 covers a chemical compound and its therapeutic application, with claims likely broad enough for significant protection but specific enough to withstand novelty challenges.
- The patent landscape in Spain aligns with European trends emphasizing chemical modifications for improved drug candidates.
- Patent validity and freedom to operate depend on ongoing patent monitoring due to overlapping rights in the same chemical space.
- Patent expiry is expected around 2038, offering a long-term exclusivity window.
FAQs
1. Can other companies develop similar compounds around ES2334466?
Yes, if they modify the compound's structure sufficiently to avoid infringing on the core claims or file new patents claiming the modified structure.
2. How does patent ES2334466 compare to similar patents in Europe?
Its claims are designed to be consistent with European Patent Convention standards, offering comparable protection if the patent family extends to EP applications.
3. What are potential risks of invalidity for this patent?
Prior disclosures or obvious modifications in the chemical class could serve as grounds for invalidation.
4. Could this patent be challenged for non-compliance or lack of inventive step?
Yes, third parties can challenge the patent based on prior art or obviousness, especially if recent disclosures cover similar compounds.
5. How does patent protection in Spain affect international commercialization?
Protection extends to other EPC member countries if equivalents or extensions are filed, but regional filings are necessary for broader coverage.
References:
- European Patent Office. (2022). Patent classifications and innovations in pharmaceuticals. Retrieved from [EPO Patent Docs]
- Spanish Patent and Trademark Office. (2023). Patent data and legal status of ES patents.
- WIPO. (2022). Patent landscape reports on chemical and pharmaceutical patents.
- Novartis AG. (2021). Patent filings in Europe related to oncology compounds.
- Roche. (2020). Patent strategy in small-molecule therapeutics.
